File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Results of a 3-month randomized trial to examine week-by-week effects of monthly ibandronate on biochemical markers of bone resorption

TitleResults of a 3-month randomized trial to examine week-by-week effects of monthly ibandronate on biochemical markers of bone resorption
Authors
Issue Date2006
PublisherSpringer-Verlag
Citation
IOF World Congress on Osteoporosis, Toronto, Canada, 2-6 June 2006. In Osteoporosis International, 2006, v. 17 n. S2, p. S218-S219 Abstract no. P334SA How to Cite?
AbstractAims: Bisphosphonates (BPs) bind preferentially to active bone remodeling sites where they decrease bone resorption through direct effects on osteoclasts. The number and depth of active bone resorption sites are considered important determinants of bone strength and fracture risk. Because resorption at a remodeling site is typically completed within 2–3 weeks, some resorption sites may proceed to completion if BPs are given at intervals greater than 1–2 weeks. We examined the pattern of urinary and serum resorption marker levels with monthly dosing of oral ibandronate, since no data are available on the effect of a monthly regimen on bone markers in the interval between doses. Methods: After a 4-week run-in of calcium and vitamin D, 203 postmenopausal osteoporotic women were randomized to receive 3 once-monthly doses of ibandronate 100 mg or 150 mg, or matching placebo. Patients and all study staff remained blinded to treatment allocation throughout the study. Serum CTx and urine NTx were measured at baseline (Week 0, just prior to first dose), one and 4 weeks after each dose and weekly after the third dose (Weeks 9–12). Geometric mean percent change from baseline was determined. Results: In each cycle, sCTx and uNTx decreases were less 4 weeks post-dose of ibandronate than at one week post-dose. Mean marker levels in ibandronate groups increased progressively throughout the 4 weeks following the third dose of ibandronate, but remained below placebo at all time points. Conclusions: Both sCTx and uNTx exhibited cyclic reductions with monthly dosing of oral ibandronate. The clinical implications of this effect are unknown and merit further investigation.
Persistent Identifierhttp://hdl.handle.net/10722/101254
ISSN
2015 Impact Factor: 3.445
2015 SCImago Journal Rankings: 1.460

 

DC FieldValueLanguage
dc.contributor.authorKung, AWCen_HK
dc.contributor.authorRovayo, Ren_HK
dc.contributor.authorGeusens, Pen_HK
dc.contributor.authorWalliser, Jen_HK
dc.contributor.authorVerbruggen, Nen_HK
dc.contributor.authorShivaprakash, Men_HK
dc.contributor.authorWehren, LEen_HK
dc.contributor.authorMelton, MEen_HK
dc.date.accessioned2010-09-25T19:42:08Z-
dc.date.available2010-09-25T19:42:08Z-
dc.date.issued2006en_HK
dc.identifier.citationIOF World Congress on Osteoporosis, Toronto, Canada, 2-6 June 2006. In Osteoporosis International, 2006, v. 17 n. S2, p. S218-S219 Abstract no. P334SA-
dc.identifier.issn0937-941X-
dc.identifier.urihttp://hdl.handle.net/10722/101254-
dc.description.abstractAims: Bisphosphonates (BPs) bind preferentially to active bone remodeling sites where they decrease bone resorption through direct effects on osteoclasts. The number and depth of active bone resorption sites are considered important determinants of bone strength and fracture risk. Because resorption at a remodeling site is typically completed within 2–3 weeks, some resorption sites may proceed to completion if BPs are given at intervals greater than 1–2 weeks. We examined the pattern of urinary and serum resorption marker levels with monthly dosing of oral ibandronate, since no data are available on the effect of a monthly regimen on bone markers in the interval between doses. Methods: After a 4-week run-in of calcium and vitamin D, 203 postmenopausal osteoporotic women were randomized to receive 3 once-monthly doses of ibandronate 100 mg or 150 mg, or matching placebo. Patients and all study staff remained blinded to treatment allocation throughout the study. Serum CTx and urine NTx were measured at baseline (Week 0, just prior to first dose), one and 4 weeks after each dose and weekly after the third dose (Weeks 9–12). Geometric mean percent change from baseline was determined. Results: In each cycle, sCTx and uNTx decreases were less 4 weeks post-dose of ibandronate than at one week post-dose. Mean marker levels in ibandronate groups increased progressively throughout the 4 weeks following the third dose of ibandronate, but remained below placebo at all time points. Conclusions: Both sCTx and uNTx exhibited cyclic reductions with monthly dosing of oral ibandronate. The clinical implications of this effect are unknown and merit further investigation.-
dc.languageengen_HK
dc.publisherSpringer-Verlag-
dc.relation.ispartofOsteoporosis Internationalen_HK
dc.titleResults of a 3-month randomized trial to examine week-by-week effects of monthly ibandronate on biochemical markers of bone resorptionen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailKung, AWC: awckung@hku.hken_HK
dc.identifier.authorityKung, AWC=rp00368en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00198-006-0095-0-
dc.identifier.pmid16645777-
dc.identifier.hkuros118520en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats